Search

CN

搜索
imgboxbg

Products

>
>
>
>
HemaSeq Human 260 Gene Mutation Detection Kit (NGS-for Illumina)
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part F_3504x2613
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part A_3504x2613
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part B_3504x2613
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part C_3504x2613
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part D_3504x2613
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part E_3504x2613
捕获法-全套_3700x2613

HemaSeq Human 260 Gene Mutation Detection Kit (NGS-for Illumina)

Product introduction Targeted-capture NGS technology is applied to detect B-cell lymphoma-related 260 genes simultaneously. SNV, Indel and splicing can be obtained in the core target regions of 260 genes all at once.
Cat. No.:
S0868-S
Spec:
6 rxns/Kit(60 Tests)
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part F_3504x2613
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part A_3504x2613
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part B_3504x2613
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part C_3504x2613
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part D_3504x2613
HemaSeq人类260基因突变检测试剂盒(可逆末端终止测序法)-Part E_3504x2613
捕获法-全套_3700x2613
Product description
Parameters

 

Detection Content

 

NGS technology enables the detection of mutations  in 260 gene associated with various signaling pathways involved in B-cell lymphoma pathogenesis, which can assist in the diagnosis, differential diagnosis, prognosis and treatment (see the gene list for details).

 

Advantages

 

1. Covers related genes on various signaling pathways of pathogenesis and key genes in WHO, NCCN, guidelines of Chinese Society of Clinical Oncology (CSCO) lymphoid malignancies, Chinese guidelines for diagnosis and treatment of B-cell lymphoma subtypes, expert consensuses and authoritative literature to assist clinical decision-making and meet scientific research needs.

 

2. Covers library preparation reagents, hybrid capture reagents, and probes for 260 genes in Kit components (of which BCL2, BCL6, and MYC genes include common fusion genes and some chemotherapy-related SNP sites);

 

3. flexible with Illumina and ThermoFisher sequencing platforms.

 

4. High sensitivity, with accurate and stable detection of 1% mutation frequency.

 

 

 

Target Population

 

To meet the clinical needs of B-cell lymphoma, a gene detection panel has been designed specifically for clinical use. This panel is informed by the NCCN guidelines, WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (2008 and 2016 revisions), guidelines of the Chinese Society of Clinical Oncology (CSCO) for lymphoid malignancies, Chinese guidelines for diagnosis and treatment of B-cell lymphoma subtypes, expert consensuses, authoritative classics, and the latest literature. The resulting gene panel is tailored to the actual clinical needs of practitioners, ensuring that it assists with disease diagnosis, differential diagnosis, prognosis, and treatment. This panel is applicable to patients with CLL/SLL, DLBCL, FL, BL, MCL, MZL, HCL, WM, and other common B-cell lymphoma.

 

 

Gene List (only partial genes displayed)

 

ACTB

ARID1A

KDM6A

KRAS

BCL10

BRAF

ACTG1

ARID1B

KDR

LRP1B

BCL11A

BTG1

ADCYAP1

ARID2

KIAA1614

LYN

BCL2

BTG2

AKT1

ATM

KIF1C

MAP2K1

BCL2L1

BTK

ALDH18A1

ATP6AP1

KLF2

MAP3K14

BCL6

LCOR

ALDH3A2

ATP6AP2

KLHL14

MAP3K7

BCL7A

CAMK2A

ALK

ATP6V0A1

KLHL6

MAPK1

BCOR

CARD11

AMOTL1

ATP6V1B2

KMT2A

MCL1

BIRC3

CASP10

ANKRD17

ATP6V1F

KMT2C

B2M

BIRC6

CBFA2T3

APC

JUNB

KMT2D

ADGRB1

BMI1

CCND1

 

 

Ordering Information

 

Cat. No. Product Strength
S0868-S

 

HemaSeq Human 260 Gene Mutation Detection Kit
(NGS-for Illumina)

 

6 rxns/Kit

(60 Tests)

 

Scan the QR code to read on your phone
We could not find any corresponding parameters, please add them to the properties table

Copyright:Wuhan Healthy Biotechnology Co., Ltd.